Advertising Standards Council of India (ASCI)
Health-Related Decisions and Recommendations

January 2015

The Advertising Standards Council of India (ASCI) is a voluntary, self-regulatory organization for India's advertising industry. The council and its Consumer Complaints Council (CCC) evaluate complaints from consumers and industry which assert that advertisements are false, misleading, indecent, illegal, leading to unsafe practices, and/or or unfair to competition, and therefore violate the ASCI Code for Self-Regulation in Advertising. In January, the complaints that were upheld against health-related claims included:

Stem Cell Advertisements

Complaints against advertisements showcasing stem cell therapies that are being investigated and experimented upon, hence NAC-SCRT has banned advertising stem cell based therapies other than hematopoietic stem cell transplantation for hematological disorders on web-sites. Such advertisements demonstrate misleading facts and experimental status of particular indication of stem cell technology. Thus the CCC concluded that the contents of the following Websites implying stem cell therapy for unapproved indications in India and violating The National Guidelines for Stem Cell Research 2013 were in breach of the law and contravened Chapter III.4 of the ASCI Code and were UPHELD:

We Care Health Service, Stem Cell Cure (P) Ltd, Unistem Biosciences, Moolchand Medicity, Stem Rx Bio Science Solutions, Stemade Biotech Pvt. Ltd, Dr. Rajput's Orthopaedic & Stem Cell Research Center, Dr. Ameet Pisapati Clinic, Neurogen Brain And Spine Institute, Stemcure Pvt Ltd., International Stem Cell Services, Inamdar Multispeciality Hospital, Chaitanya Stem Cell Centre, Noble Hospital, Giostar, K. G Hospital, Saviour Hospital, Safemedtrip Consultants Pvt. Ltd, We Care India, Indiacarez, Reelabs Pvt Ltd., KMC Speciality Hospital and Placidway.

Other Advertisements

This page was posted on January 28, 2017.

Links to Recommended Companies